Bladder cancer represents a major health care burden in many societies. Currently, cystoscopy and urinary cytology are the gold standard in bladder cancer detection. To further improve detection and/or to reduce expensive and invasive cystoscopies, highly sensitive and specific urine-based tumour markers are requested. Until now, several urine-based tumour markers for the detection and surveillance of bladder cancer have been developed and are commercially available. Others are under research. This paper gives an overview of the currently commercially available urine-based tumour makers for bladder cancer. Information is based on a non-systematic PubMed literature search. All markers were at least in some studies superior to urinary cytology; however, none of them can be considered sensitive and specific enough alone to substantially reduce the necessity of cystoscopies. The recommended use of urine-based tumour markers therefore remains in adjunction to cystoscopy and for some of them in individual screening situations of patients at high risk.


Copyright © 2012, Kowsar M.P.Co. All rights reserved.


"/> Bladder cancer represents a major health care burden in many societies. Currently, cystoscopy and urinary cytology are the gold standard in bladder cancer detection. To further improve detection and/or to reduce expensive and invasive cystoscopies, highly sensitive and specific urine-based tumour markers are requested. Until now, several urine-based tumour markers for the detection and surveillance of bladder cancer have been developed and are commercially available. Others are under research. This paper gives an overview of the currently commercially available urine-based tumour makers for bladder cancer. Information is based on a non-systematic PubMed literature search. All markers were at least in some studies superior to urinary cytology; however, none of them can be considered sensitive and specific enough alone to substantially reduce the necessity of cystoscopies. The recommended use of urine-based tumour markers therefore remains in adjunction to cystoscopy and for some of them in individual screening situations of patients at high risk.


Copyright © 2012, Kowsar M.P.Co. All rights reserved.


"/>

Currently Available Urine-Based Tumour Markers in the Detection of New and Recurrent Urothelial Bladder Cancer

AUTHORS

Marcus Horstmann 1 , *

1 Department of Urology, Kantonsspital Winterthur, [email protected], Switzerland

How to Cite: Horstmann M . Currently Available Urine-Based Tumour Markers in the Detection of New and Recurrent Urothelial Bladder Cancer, Nephro-Urol Mon. Online ahead of Print ; 4(1):345-349. doi: 10.5812/kowsar.22517006.1841.

ARTICLE INFORMATION

Nephro-Urology Monthly: 4 (1); 345-349
Published Online: December 19, 2011
Article Type: Review Article
Received: July 5, 2011
Accepted: July 29, 2011
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Bladder cancer represents a major health care burden in many societies. Currently, cystoscopy and urinary cytology are the gold standard in bladder cancer detection. To further improve detection and/or to reduce expensive and invasive cystoscopies, highly sensitive and specific urine-based tumour markers are requested. Until now, several urine-based tumour markers for the detection and surveillance of bladder cancer have been developed and are commercially available. Others are under research. This paper gives an overview of the currently commercially available urine-based tumour makers for bladder cancer. Information is based on a non-systematic PubMed literature search. All markers were at least in some studies superior to urinary cytology; however, none of them can be considered sensitive and specific enough alone to substantially reduce the necessity of cystoscopies. The recommended use of urine-based tumour markers therefore remains in adjunction to cystoscopy and for some of them in individual screening situations of patients at high risk.


  • Implication for health policy/practice/research/medical education:
    Urine-based tumour markers might become a helpful tool in early detection of bladder cancer. This review is adressed to health professionals dealing with bladder cancer patients and patients at risk.
  • Please cite this paper as:
    Horstmann M. Currently Available Urine-Based Tumour Markers in the Detection of New and Recurrent Urothelial Bladder Cancer. Nephro-Urol Mon.2012;4(1): 345-9.DOI: 10.5812/kowsar.22517006.1841

Copyright © 2012, Kowsar M.P.Co. All rights reserved.


Full Text

Full text is available in PDF

© 2011, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: